CA
NZ
UK
AU
IND
US
…
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms. HeartBeam, Inc. was incorporated in 2015 and is based in Santa Clara, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
HeartBeam Inc develops smartphone-enabled cardiac diagnostic devices and algorithms intended to detect acute cardiac ischemia and enable remote electrocardiographic monitoring. Long-term growth may be supported by aging populations, expanded telehealth adoption and demand for earlier out-of-hospital cardiac detection. Investors may find the company interesting for its portable, patient-facing approach and potential to address gaps in emergency and ambulatory diagnostics.
Key risks include reliance on successful regulatory approvals and clinical validation, uncertain reimbursement and adoption in clinical workflows, competition from established medical-device and digital-health companies, limited commercial revenue to date and potential need for additional financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -21.02M | -19.45M | -14.64M | -12.96M | -4.43M |
| Net income | -21.02M | -19.45M | -14.64M | -12.83M | -6.59M |
| Selling general administrative | 7.69M | 8.84M | 8.52M | 7.35M | 2.03M |
| Selling and marketing expenses | - | - | 8.51M | - | - |
| Gross profit | -0.04M | -0.01M | - | - | - |
| Reconciled depreciation | 0.04M | 0.01M | 0.00M | - | - |
| Ebit | -21.18M | -19.89M | -14.64M | -13.03M | -2.29M |
| Ebitda | -21.14M | -19.88M | 0.68M | -13.03M | -2.26M |
| Depreciation and amortization | 0.04M | 0.01M | 15.31M | 0.14M | 0.02M |
| Operating income | -21.14M | -19.89M | -15.31M | -13.03M | -2.29M |
| Other operating expenses | 21.14M | 19.89M | 15.31M | 13.03M | 2.29M |
| Interest expense | - | - | - | 0.07M | 2.17M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.12M | 0.45M | 0.68M | - | - |
| Net interest income | 0.12M | 0.45M | 0.47M | 0.07M | -2.17M |
| Income tax expense | - | - | -0.02M | -0.14M | 2.17M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 21.14M | 19.89M | 15.31M | 13.03M | 2.29M |
| Cost of revenue | 0.04M | 0.01M | - | - | - |
| Total other income expense net | 0.12M | 0.44M | 0.68M | 0.07M | -2.14M |
| Net income from continuing ops | -21.02M | -19.45M | -14.47M | -12.96M | -4.43M |
| Net income applicable to common shares | - | - | - | -12.96M | -4.43M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5.84M | 3.28M | 17.13M | 4.04M | 14.00M |
| Other current assets | 0.20M | 0.39M | 0.64M | 0.45M | 0.81M |
| Total liab | 3.24M | 1.62M | 1.19M | 1.67M | 0.59M |
| Total stockholder equity | 2.60M | 1.65M | 15.94M | 2.37M | 13.41M |
| Other current liab | 3.24M | 1.09M | 1.19M | 1.67M | 0.59M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -77.29M | -56.27M | -36.83M | -22.19M | -9.22M |
| Other assets | - | - | - | 0.45M | 0.81M |
| Cash | 4.38M | 2.38M | 16.19M | 3.59M | 13.19M |
| Total current liabilities | 3.24M | 1.62M | 1.19M | 1.67M | 0.59M |
| Net debt | -4.38M | -2.38M | -16.19M | -3.59M | -13.19M |
| Other stockholder equity | 79.89M | 57.92M | 52.76M | 24.56M | 22.63M |
| Total current assets | 4.68M | 2.77M | 16.82M | 4.04M | 14.00M |
| Net tangible assets | - | - | - | 2.37M | 13.41M |
| Inventory | 0.10M | 0.00M | - | - | - |
| Accounts payable | 1.05M | 0.53M | 0.00M | 0.00M | 0.59M |
| Non currrent assets other | 0.06M | 0.06M | 0.05M | - | - |
| Non current assets total | 1.16M | 0.51M | 0.31M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -0.20M | -0.26M | 0.00M | - |
| Change to liabilities | - | - | - | 1.53M | -0.36M |
| Total cashflows from investing activities | -0.60M | -0.20M | - | - | - |
| Net borrowings | - | - | - | - | 1.69M |
| Total cash from financing activities | 16.59M | 0.87M | 24.99M | 0.35M | 16.40M |
| Change to operating activities | - | - | - | 0.36M | -0.78M |
| Net income | -21.02M | -19.45M | -14.64M | -12.96M | -4.43M |
| Change in cash | 2.00M | -13.81M | 12.64M | -9.60M | 13.17M |
| Begin period cash flow | 2.43M | 16.24M | 3.59M | 13.19M | 0.02M |
| End period cash flow | 4.44M | 2.43M | 16.24M | 3.59M | 13.19M |
| Total cash from operating activities | -13.99M | -14.47M | -12.09M | -9.95M | -3.23M |
| Issuance of capital stock | 16.58M | 0.73M | 24.76M | 0.35M | 14.71M |
| Depreciation | 0.04M | 0.01M | - | - | - |
| Change to inventory | -0.10M | 0.00M | - | - | - |
| Other cashflows from financing activities | 16.59M | 0.14M | 0.23M | 0.00M | 1.72M |
| Change to netincome | - | - | - | 1.12M | 2.33M |
| Capital expenditures | 0.60M | 0.20M | 0.26M | 0.00M | 0.00M |
| Change in working capital | 1.61M | 0.67M | -0.66M | 1.89M | -1.14M |
| Stock based compensation | 5.15M | 4.30M | 3.21M | 1.12M | 0.19M |
| Other non cash items | 0.23M | 0.67M | 3.21M | 1.12M | 2.14M |
| Free cash flow | -14.59M | -14.67M | -12.35M | -9.95M | -3.23M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| BEAT Heartbeam Inc |
0.01 2.06% |
0.55 | - | - | - | 18.96 | -2.99 |
| VEEV Veeva Systems Inc Class A |
2.62 0.84% |
312.96 | 43.49 | 29.59 | 12.48 | 5.79 | 33.41 |
| PMCUF Pro Medicus Limited |
- -% |
137.03 | 64.90 | 90.91 | 49.11 | 38.05 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
-5.62 7.22% |
72.22 | - | - | 8.68 | 25.39 | - |
| MTHRY M3 Inc |
-0.03 0.52% |
5.77 | 31.84 | 26.25 | 0.05 | 4.60 | 0.12 |
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms. HeartBeam, Inc. was incorporated in 2015 and is based in Santa Clara, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard M. Ferrari | Exec. Chairman | 1954 |
| Dr. Branislav Vajdic Ph.D. | Founder, Pres, CEO & Director | 1955 |
| Mr. Richard D. Brounstein | CFO & Treasurer | 1950 |
| Mr. Ken Persen | Chief Technology Officer | NA |
| Dr. Jon Hunt Ph.D. | Exec. VP & Chief Bus. Officer | 1956 |
| Dr. Peter J. Fitzgerald FACC, M.D., Ph.D. | Chief Medical Officer | 1957 |
| Mr. Richard M. Ferrari | Executive Chairman | 1954 |
| Dr. Branislav Vajdic Ph.D. | Founder, CEO & Director | 1955 |
| Mr. Robert P. Eno | President & Chief Business Officer | NA |
| Mr. Kenneth Persen | Chief Technology Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...